1. (valid email required)
 

cforms contact form by delicious:days

CRi Biomedical Imaging Systems Used by World’s Top Pharmaceutical Companies

February 23, 2010

Biotechnology Leader Provides Technology of Choice for Leading Pharmaceutical Industry Scientists

Woburn, Massachusetts – January 27, 2010

Cambridge Research & Instrumentation, Inc. (CRi), a leader in biomedical imaging, announced that 18 out of the top 20 pharmaceutical companies worldwide are using CRi’s optical imaging systems. These top pharmaceutical companies, ranked by revenue by Med Ad News in September 2009, have chosen CRi systems for molecular-based drug development and research.

There is a growing consensus among scientists that fulfilling the promise of molecular medicine requires a shift from the study of single events to viewing complex biological systems in their entirety. CRi’s integrated imaging products provide researchers and clinicians with quantitative assessments of disease and drug response. This is accomplished by evaluating multiple markers simultaneously in intact tissue samples, at a cellular level or in living small animals. CRi’s solutions have received strong industry recognition for having a significant impact in translational and clinical research and applications.

“The acceptance of CRi solutions by the world’s leading pharmaceutical companies further establishes the trend for drug development efforts, particularly in areas such as oncology, to focus on developing targeted therapies for more molecularly defined patient populations,” said George Abe, chief executive officer at CRi. “Researchers realize the significant capabilities of CRi’s platform technology and the efficiency and productivity gains that they provide, along with the potential to translate into diagnostic applications.”

CRi’s diverse and applications-focused products have revolutionized fluorescence and brightfield microscopy, in vivo imaging and assisted reproductive technologies. Based on its proprietary technology, CRi systems enable researchers to better explore biological pathways in drug development and personalized medicine by bridging the gap between combinatorial chemistry, flow cytometry and morphological imaging.

About CRi

Cambridge Research & Instrumentation, Inc. (CRi) develops and markets optical imaging systems to advance biomedical research and molecular-based drug and diagnostic development. CRi’s patented systems enable researchers and clinicians to quantitate multiple disease and drug response markers in intact tissue samples, at a cellular level or in living small animals. CRi’s products integrate a unique multispectral imaging technology with proprietary image analysis algorithms to achieve unparalleled accuracy and sensitivity, rapidly and cost-effectively. CRi’s award-winning systems include Nuance™ for multispectral imaging on brightfield and fluorescence microscopes; inForm™ automated image analysis software; Vectra™ for high-throughput slide imaging and analysis; and Maestro™ for in-vivo optical imaging. Learn more at www.cri-inc.com.

For more information, contact:

Cambridge Research & Instrumentation, Inc. (CRi)

Cathy Boutin, 781-935-9099

Marketing Manager

cboutin@cri-inc.com

or

Commonwealth Creative Associates

Jamie Bull, 508-620-0791

Digital Media Strategist

jamieb@commcreative.com

or

Commonwealth Creative Associates

Donna Phelps, 508-620-0791

Senior Account Executive

donnap@commcreative.com

Latest News

Dynasil Corporation of America (NASDAQ:DYSL) is pleased to announce our new website is now available at www.dynasil.com

NWN Corporation Obtains Cisco’s Elite Partnership Status In Their OpenDNS Certification Partner Program

NWN Corporation Named to CRN’s 2016 IT Solutions Provider 500 List

ACT Government leads in waste innovation

Zenoss Names NWN Corporation as Managed IT Service Provider of The Year For Second Year In a Row

Datawatch Enables 450 CNAF Accountants to Prep Less and Analyze More

NWN Completes “Cisco Mega Audit” – Achieves Multiple “Master” Certifications

Best Practices for Pharmaceutical Waste


Latest Newsletters

July 2016 – Mass Capital Announces a New Investment in The Cadmus Group, Inc.

April 2016 – Andrew DeLorey joins Mass Capital

March 2016 – Mass Capital announces a new investment in Valet Park of America

January 2016 – Mass Capital announces a new investment in Phillips Screw Company

November 2015 – Mass Capital announces a new investment in Triumvirate Environmental

September 2015 – Mass Capital announces a new investment in MedTouch

September Newsletter 2014

Mass. Capital Announces Addition to Investment Team